S-1/A: First Choice Healthcare Pivots to Wellness, Seeks $19M IPO

First Choice Healthcare Solutions, Inc. is undergoing a major strategic pivot from orthopedics to primary care and wellness clinics, seeking to raise $19 million in an IPO to fund acquisitions and growth despite a history of significant losses.

Summary

• First Choice Healthcare Solutions, Inc. (FCHS) is shifting its business strategy from orthopedic services to developing a national chain of primary care and wellness clinics, focusing on anti-aging, weight management, and hormone replacement services.
• The company plans to acquire Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC (collectively 'Pointe Med Pharmacy') for $15.8 million, payable in cash, debt assumption/payoff, stock, earn-out, and performance bonus.
• FCHS also intends to acquire the physical and intangible assets of The Good Clinic, Inc. for $3.5 million in an all-stock deal.
• The company is offering up to 3,800,000 shares of Series D Convertible Preferred Stock and warrants to purchase an equal number of Series D Preferred Stock, with an assumed combined public offering price of $5.00 per share and warrant.
• The IPO aims to raise approximately $17.08 million in net proceeds (or $19.702 million if the over-allotment option is fully exercised), with $9 million allocated for acquisitions.
• A 1-for-2,000 reverse stock split was approved by the Board of Directors on September 15, 2024, applicable to existing common stock shareholders prior to NYSE listing, but not to shares issued in the IPO, resale shares, or shares related to acquisitions/debt exchanges.
• The IPO is contingent on raising at least $15.0 million to meet NYSE listing requirements; failure to do so will prevent the IPO, acquisitions, and debt exchanges from closing.
• Selling stockholders are offering up to 3,000,010 shares of common stock for resale at a fixed price of $5.00 per share until NYSE listing, which are not subject to the reverse stock split.
• FCHS reported net losses of $3.5 million for the nine months ended September 30, 2025, and $3.8 million for the year ended December 31, 2024, with an accumulated deficit of $71.3 million as of September 30, 2025.
• Pointe Med/LiveWell, the acquired entity, reported net income of $1.44 million for the nine months ended September 30, 2025, and $1.41 million for the year ended December 31, 2024, with a gross profit margin of 85% in 2025.
• The company's ability to continue as a going concern is dependent on successfully executing its business development plan, including acquisitions, revenue growth, cost reduction, and securing additional capital.

Sentiment

Score: 4

Explanation: The company faces significant historical financial challenges, including recurring losses and a going concern doubt, stemming from past issues and bankruptcy. However, the strategic pivot into a high-growth healthcare segment (primary care and wellness) with a differentiated model and the positive historical performance of the acquired entities offer potential for future improvement. The success of the IPO and integration of acquisitions are critical and highly speculative, making the investment high-risk but with potential upside if the new strategy is successfully executed.

Positives

• The acquired entity, Pointe Med/LiveWell, has demonstrated positive net income and cash flow from operations, with a gross profit margin of 85% for the nine months ended September 30, 2025.
• The strategic pivot to primary care and wellness clinics, including compounding pharmacy services, targets high-growth healthcare market segments.
• The new business model leverages Nurse Practitioners for an estimated 25% labor cost advantage and aims for economies of scale through centralized administrative infrastructure.
• The company plans to offer a diversified product line, including insurance-paid primary care and higher-margin self-pay quality-of-life services and personalized medications.
• The acquisition of LiveWell Drugstore, a compounding pharmacy, provides internal capacity for personalized prescription medication, enhancing patient experience and maximizing profitability.

Negatives

• First Choice Healthcare Solutions, Inc. (FCHS) has a history of significant net losses, including $3.5 million for the nine months ended September 30, 2025, and an accumulated deficit of $71.3 million.
• The company has recurring cash outflows from operations, raising substantial doubt about its ability to continue as a going concern.
• The IPO and acquisitions are contingent on raising at least $15.0 million, and failure to do so will prevent these critical transactions from closing.
• New investors in the Series D Convertible Preferred Stock will experience immediate and substantial dilution of $4.96 per share of common stock upon conversion.
• Anti-dilution provisions in the Series D Convertible Preferred Stock could lead to an indeterminate number of shares being issued upon conversion if future securities are issued at a lower price, further diluting shareholders.
• There is no established public trading market for the Offered Preferred Stock or the Warrants, and no assurance that a market will develop, limiting liquidity.
• The company's former CEO pled guilty to securities fraud, which tarnished the company's reputation and led to bankruptcy, indicating past governance and operational issues.

Risks

• The company has posted minimal profit since commencing operations and has a limited operating history in its new strategic direction, making future performance difficult to evaluate.
• Insufficient cash from operations to meet current or future operating needs, expenditures, and debt service obligations could materially adversely affect the business.
• Failure to raise additional capital will require curtailment or cessation of operations.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or assets.
• Opening new clinics in multiple markets may strain resources and management, leading to operating inefficiencies or failure to achieve planned growth.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• Quarterly financial results are expected to fluctuate significantly due to demand for services, client retention, economic conditions, and marketing costs.
• Volatility in financial markets could make future financing difficult or more expensive.
• Potential profit margins may decline due to increasing pricing pressure in the industry.
• High indebtedness ($24.7 million as of December 31, 2024) could divert cash flow, reduce financial flexibility, and expose the company to increased interest rates.
• Pandemics, natural disasters, terrorist activities, and other outbreaks could disrupt clinic operations and adversely impact the business.
• Acquisitions involve risks related to integration difficulties, achieving anticipated benefits, and maintaining effective internal controls.
• Inability to attract and retain qualified medical professionals (Nurse Practitioners) could negatively affect operations and expansion.
• Exposure to medical professional liability risks, which could be costly and divert management attention.
• Significant operational and financial risks associated with billing Medicare, Medicaid, and TriCare, including compliance risks, fraud allegations, payment delays, and audit risks.
• Operating primary care clinics in multiple states with varying commercial payer contracts creates administrative complexity and compliance risks.
• Evolving healthcare regulatory and political framework could adversely affect financial condition and results of operations.
• The practice of pharmacy is highly regulated, and failure to comply with state and federal laws could limit compounding pharmacy revenue growth.
• Compounding pharmacies are dependent on consistent availability and quality of base pharmaceuticals; supply chain disruptions could significantly decrease revenue and service scope.
• Federal and state laws protecting patient privacy (HIPAA, HITECH) may increase costs and limit data use, subjecting the company to penalties for non-compliance.
• Reliance on the self-pay model for quality-of-life services introduces revenue volatility, bad debt risk, pricing challenges, and administrative costs.
• Changes in third-party reimbursement rates or methods could reduce demand for services or create downward pricing pressure.
• Restrictions on advertising by federal and state laws may adversely affect the ability to promote clinics and services.
• Failure to achieve and maintain internal controls in accordance with Sarbanes-Oxley Act could harm business and stock price.
• The market for healthcare services is highly competitive, with larger, better-financed competitors, which could lead to reduced demand or pricing pressure.
• A decline in consumer disposable income could adversely affect clinical visits and financial results.
• The company is a smaller reporting company, and reduced disclosure requirements may make its common stock less attractive to investors.
• Requirements of being a public company may strain resources and distract management.
• Management has broad discretion in the use of IPO proceeds, which may not be used effectively.
• Limited trading market for common stock to date, and no public market for Preferred Stock or Warrants, limiting liquidity.
• The market price of common stock may fluctuate significantly due to various factors, including regulatory changes, reimbursement policies, and operating results.
• A significant percentage of common stock is held by a small number of shareholders, potentially influencing shareholder votes.
• Issuance of common stock from warrants held by selling stockholders could cause substantial dilution.
• Resales by selling stockholders may adversely affect the market price of common stock.
• The company has not paid dividends in the past and has no immediate plans to do so.
• Penny stock rules may make buying or selling securities difficult, reducing liquidity.

Future Outlook

The company's future outlook is centered on a strategic pivot to developing a national chain of innovative primary care and wellness clinics, leveraging two key acquisitions (Pointe Med Pharmacy group and The Good Clinic assets). This strategy aims to redefine primary care through personalized care plans, a broad spectrum of healthcare services, and internal compounding pharmacy operations. The company anticipates achieving economies of scale and improved financial performance by focusing on Nurse Practitioners and a scalable back-office system. Operations for the new primary care and wellness clinics are expected to commence by March 1, 2026. However, the success of this pivot is subject to significant risks, including securing sufficient financing, integrating acquisitions, and navigating a highly competitive and regulated healthcare market.

Management Comments

• Management made the strategic decision to pivot away from the orthopedic services model to leveraging our management services infrastructure to support the development and growth of a national chain of branded primary care and wellness clinics following our exit from bankruptcy.
• We are confident in the market size of our business opportunity, the strength of our strategy, and the experience of our management team.
• Our strategy of combining a full suite of primary care services and the specialized services of our competition in an operational environment focused on providing high quality care, excellent customer experience, personalized care plans and personalized medications has the potential to deliver our desired financial performance.
• Our centralized system of administrative infrastructure will allow us to achieve measurable cost and productivity efficiencies, as we expand the number of clinics we own and operate.
• It is our plan that the cost of our back-office operations will not increase in direct relation to the growth of our network of primary care clinics, which will allow us to sustain profit margins across our business operations with a cost effective and scalable back office.

Industry Context

The U.S. healthcare market is experiencing significant growth, with expenditures increasing 4.1% to $4.5 trillion in 2022, representing 17.3% of GDP, and projected to reach $7.1 trillion (19.6% of GDP) by 2031. This unsustainable trajectory highlights an urgent need for expanded access to primary care. The U.S. primary care market alone was valued at $271.0 billion in 2023, with an expected CAGR of 3.36% from 2024 to 2030. The company's pivot into personalized primary care, wellness, and compounding pharmacy services aligns with this trend, addressing the demand for more effective, cost-conscious, and patient-centric healthcare solutions. The market is highly competitive, with established virtual, brick-and-mortar, and specialized clinics, requiring the company to differentiate through superior service and medical outcomes.

Comparison to Industry Standards

• Nurse Practitioners, who will primarily staff the company's clinics, offer an approximate 25% margin improvement over traditional primary care offices staffed with medical doctors, while studies indicate they deliver care equal to or better than physicians.
• The company's strategy of combining a full suite of primary care services with specialized quality-of-life services (anti-aging, hormone replacement, weight management) and an internal compounding pharmacy aims to differentiate it from competitors like Hims, Ro, REX MD (virtual), Revibe, Herself Health, Oak Street Medical, One Medical (brick-and-mortar), and individual private practices.
• The company's EMR system complies with Stages 1 and 2 Meaningful Use standards, allowing it to earn incentive payments from the U.S. government, aligning with industry best practices for electronic health records.

Management Changes

Corporate Governance

Legal Proceedings

• The company's former Chief Executive Officer, Christian C. Romandetti, Sr., pled guilty to conspiracy to commit securities fraud, which led to the company filing for Chapter 11 bankruptcy.
• The company was involved in multiple legal proceedings that were settled or converted into unsecured creditors as part of its bankruptcy reorganization plan.
• An open accounts payable liability of approximately $1,200,000 remains from a lease settlement expense related to the Marina Towers lease, with the company working to reach a settlement with the landlord.
• A $19,473 judgment was granted against the company in January 2024 for an equipment lease, which was subsequently negotiated down to a $9,000 settlement.
• The company has an accrued liability of $84,051 related to collection costs and remaining lease payments for a care facility lease agreement with CBL & Associates Properties, Inc.
• A motion for summary judgment was granted against the company for $102,884 (including attorney fees and costs) in a breach of lease agreement case filed by MBABJB Holdings Family Limited Partnership.
• The company has an unpaid legal fee balance of $203,115 to Ackerman, LLP, from its bankruptcy proceedings, for which a motion for summary judgment was granted.
• The company is a defendant in several employment-related matters, primarily due to unpaid wages following staff reductions and terminations, with most cases settled.

Related Party Transactions

• Notes payable include $2,142,105 due to the company's Chief Executive Officer (Lance Friedman) and $151,858 due to the company's prior Chief Financial Officer as of September 30, 2025, related to deferred compensation, payments to third-party service providers, and other normal course of business items.
• Pointe Medical Live Well group leases space under an operating lease agreement dated October 1, 2019, with Live Well Realty, LLC, which is a related party.

Stakeholder Impact

• **Shareholders (Existing)**: Will experience significant dilution from the proposed 1-for-2,000 reverse stock split and the issuance of new shares in the IPO and acquisitions. Their voting power will be diluted, but the cancellation of Series A Super Voting Preferred Stock will remove concentrated control.
• **Shareholders (New Investors in IPO)**: Will face immediate and substantial dilution ($4.96 per share) and high investment risk due to the company's history of losses and the speculative nature of the strategic pivot. However, they are investing in a company with a new growth strategy in a growing market.
• **Selling Stockholders (Resale Offering)**: Will be able to sell up to 3,000,010 shares at a fixed price of $5.00 per share, providing liquidity for their investments, which were made with anti-dilution protection against the reverse split.
• **Employees/Medical Professionals**: The strategic pivot involves hiring key personnel, including Nurse Practitioners, and aims to provide a compelling alternative to other employment, potentially creating new job opportunities and a focused work environment.
• **Customers/Patients**: The new strategy aims to provide patient-centric personalized care, a broad spectrum of primary care and wellness services, and personalized medications through an internal compounding pharmacy, potentially leading to improved healthcare experiences and outcomes.
• **Creditors**: The IPO proceeds will be used in part to settle certain notes payable and other liabilities, which could improve the company's financial stability and ability to meet obligations. The bankruptcy proceedings converted many claims to unsecured status, with some settlements still ongoing.

Next Steps

• Complete the public offering of Series D Convertible Preferred Stock and Warrants.
• Uplist common stock to the NYSE under the symbol FCHS (or 'Leading Primary Care, Inc.' after name change).
• Complete the 100% stock purchase acquisition of Pointe Medical Services, Inc., Pointe Med Pharmacy, Inc., Livewell MD, LLC, and Livewell Drugstore, LLC for $15.8 million.
• Complete the asset purchase agreement to acquire The Good Clinic, Inc. for $3.5 million.
• Terminate all remaining legacy orthopedic and physical therapy services.
• Commence operations for the primary care and wellness clinics as part of the new strategy starting March 1, 2026.
• Appoint new board members and re-establish Audit, Nominating and Governance, and Compensation Committees in the third quarter of 2025.
• Increase the number of state licensures for LiveWell Drugstore to include each state where primary care clinics operate.
• Begin the process of attaining FDA approval for LiveWell Drugstore to become an FDA-registered 503B pharmacy.
• Expand compounding pharmacy operations to other states as the number of clinics grows.
• Actively seek additional qualified and FDA approved suppliers for raw product components for compounding pharmacy.

Key Dates

Keywords

Healthcare Solutions, Primary Care, Wellness Clinics, Compounding Pharmacy, IPO, Series D Preferred Stock, Warrants, Reverse Stock Split, SEC Filing, Accredited Investor, Healthcare Acquisitions, Nurse Practitioners, Anti-aging, Weight Management, Hormone Replacement Therapy, Medical Equipment, Electronic Medical Record, Going Concern, Dilution, NYSE Listing